Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Waldo O García-Ferrera"'
Autor:
Hugo Nodarse-Cuní, Enrique Arús-Soler, Luis L Rivera-Reimón, Marlén Pérez-Lorenzo, Marcia Samada-Suárez, Waldo O García-Ferrera, Yoan A Sánchez-Rodríguez, Daymela Pupo-Oliveros, Angel Obregón-Moreno, Ivis Umpierre-García, Orelvis Martínez-Martínez, Antonio Moret-Pérez, Yaimé González-González, Yuliet Bermúdez-Hernández, Elizeth García-Iglesias, Odalys C Lazo-Diago, Pedro López-Saura
Publikováno v:
Biotecnología Aplicada, Vol 29, Iss 3, Pp 184-188
The treatment of chronic hepatitis C with interferon alpha (IFN-a) is widely used. However, the relapse rate is high, and sustained response is only in 10-20%. A combined treatment based on the synergic antiviral effects described for IFN-a and ribav
Externí odkaz:
https://doaj.org/article/f3c2c2e4ff484170b52c4545adaabdd3
Publikováno v:
Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru. 29(3)
Since the identification of hepatitis C in 1989, it has been studied extensively. In addition to its hepatotropic; have extrahepatic effects that are directly related to extrahepatic replication with high affinity to lymphoid tissues. As a result of
Publikováno v:
Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru. 27(3)
The pregnancy supposes a deep change in the human physiology. Such changes can entail the appearance of diseases that secondarily affect the liver, like the hipermesis gravidica, HELLP syndrome, the cholestasis of pregnancy and the acute hepatic stea
Autor:
Hugo Nodarse-Cuní, Enrique Arús-Soler, Luis L Rivera-Reimón, Marlén Pérez-Lorenzo, Marcia Samada-Suárez, Waldo O García-Ferrera, Yoan A Sánchez-Rodríguez, Daymela Pupo-Oliveros, Angel Obregón-Moreno, Ivis Umpierre-García, Orelvis Martínez-Martínez, Antonio Moret-Pérez, Yaimé González-González, Yuliet Bermúdez-Hernández, Elizeth García-Iglesias, Odalys C Lazo-Diago, Pedro López-Saura
Publikováno v:
Biotecnología Aplicada, Vol 29, Iss 3, Pp 184-188
The treatment of chronic hepatitis C with interferon alpha (IFN-a) is widely used. However, the relapse rate is high, and sustained response is only in 10-20%. A combined treatment based on the synergic antiviral effects described for IFN-a and ribav